The Pfizer and BioNTech mRNA Vaccine for COVID-19 Conferred 95% Protection With a Satisfactory Safety Profile
Pfizer and BioNTech release safety and efficacy data from phase 2/3 trials for their COVID-19 mRNA vaccine.
Pfizer and BioNTech release safety and efficacy data from phase 2/3 trials for their COVID-19 mRNA vaccine.
Further research is needed to identify possible interventions that may mitigate the racial disparities seen in COVID-19.
There seems to be no causal association between COVID-19 and Guillain-Barré syndrome (GBS).
Intensive health surveillance of close contracts of patients with COVID-19 provided a rare opportunity to determine asymptomatic attack rates and SARS-CoV-2 transmission risk factors.
The next difficult task in combating the COVID-19 pandemic will be to effectively distribute the vaccine and convince sufficient numbers of individuals to be vaccinated in order for herd immunity to be successful.
For patients hospitalized with SARS-CoV-2 infection, neurologic complications include altered mental status, fatigue, headache, and stroke.
This study aimed to evaluate changes in sleep during the COVID-19 outbreak, and used data-driven approaches to identify distinct profiles of changes in sleep-related behaviors. Demographic, behavioral and psychological factors associated with sleep changes were also investigated.
Study researchers investigated whether the COVID-19 pandemic potentially contributed to the delay in acute stroke care.
Given that COVID-19 has placed a heavy burden on health care workers, this study was carried out to determine burnout levels and sleep quality of nurses during the pandemic.
The researchers compared Google search queries for the term “insomnia” from April and May 2020 to the same months in 2017, 2018, and 2019.